News

MyChesCo on MSN2h
STRATA Skin Sciences Expands Access to Excimer Laser Treatments with CPT Code Updates
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced significant progress in its mission to provide broader access to advanced ...
Medscape10h
FDA Expands Approval of Roflumilast Foam for Treating Scalp, Body Psoriasis
The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.
The American Journal of Managed Care12h
FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis
Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...
PharmExec14h
FDA Clears Investigational New Drug Application for Ascletis’ Oral IL-17 Inhibitor in Mild-to-Moderate Plaque Psoriasis
Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.
Zacks Small Cap Research on MSN14h
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis…
FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Preclinical Psoriasis Data Presented at SID Annual Meeting On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation ...
Rheumatology Advisor17h
Guselkumab Improves Biomarkers of Systemic Inflammation in Plaque Psoriasis
Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.
Ascletis Announces U.S. FDA Clearance of IND Application for Its Oral Small Molecule IL-17 Inhibitor, ASC50, for the Treatment of Psoriasis
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase I trial for ASC50 for the ...